

RESPONSE TO SGX QUERIES IN RELATION TO THE COMPANY'S ANNOUNCEMENT ON CREDITORS' VOLUNTARY LIQUIDATION OF A SUBSIDIARY

The Board of Directors (the “**Board**”) of Biolidics Limited (the “**Company**” and together with its subsidiaries, the “**Group**”) refers to the queries raised by the Singapore Exchange Securities Trading Limited (“**SGX-ST**”) on 10 June 2024 and would like to provide further information in relation to the Company’s announcement on “Creditors’ Voluntary Liquidation of a Subsidiary” (the “**Announcement**”) released by the Company on 10 June 2024.

Unless otherwise defined, capitalised terms used herein shall bear the same meaning as ascribed to them in the Announcement.

SGX Query 1:

What are the AC’s and Board’s opinion, with supporting base, on whether (i) the Company and Group can still continue as a going concern; and (ii) the Company should be deemed a cash company under Catalist Rule 1017?

The Company’s response:

The Group has two revenue streams. One is from Biolidics’s Cancer segment which involves the sales of its ClearCell® FX1 system, CTChip® FR1 biochip, and other related services and consumables (“**Cancer Segment**”) and the other one is from Biomedics’ laboratory services. Each generated approximately \$38,000 and \$3,000 in revenue, respectively, for a total of \$41,000 in 1Q FY2024. The liquidation of the subsidiary will only affect the laboratory services business, and with shareholders’ approval at the Extraordinary General Meeting (“**EGM**”) on 23 February 2024, the Group will be diversifying its business into Multi-Channel Networking, E-Sports and Live-streaming.

In addition, the Executive Director and Chairman of the Group, Mr Zhu Hua has, pursuant to his undertaking to provide financial support (as announced on 28 February 2024 and 14 May 2024), continued to extend financial support to the Group.

The AC together with the Board has considered (a) the Group’s effort in implementing sales strategy, and continued efforts to seek contracts to support its Biolidics Cancer Segment (b) business diversification plans which will bring in additional streams of revenue and (c) the financial support from Mr Zhu Hua, and are of view that the Company and the Group can still continue as a going concern and should not be deemed as a cash company.

SGX Query 2:

What is the Sponsor’s opinion, with supporting bases, on whether (i) the Company and Group can still continue as a going concern; and (ii) the Company should be deemed a cash company under Catalist Rule 1017.

The Sponsor’s response:

In addition to the Group’s implementation of cost-cutting measures, the Group has (a) implemented various sales strategy and continued its efforts to seek contracts to support its Biolidics Cancer Segment, (b) sought approval from the EGM for its business diversification which will bring in additional streams of revenue and (c) obtained an undertaking from Mr Zhu Hua to provide financial support.

The Sponsor after considering the factors above is of view that the Company and the Group can still continue as a going concern and should not be deemed as a cash company.

SGX Query 3:

Please provide the Board's confirmation that all material information has been fully disclosed via SGXNET to enable trading to continue on an informed basis.

The Company's response

The Board confirms that all material information has already been fully disclosed via announcements in SGXNET to enable trading to continue on an informed basis.

The Company will provide updates on any further material developments when necessary.

By Order of the Board

Zhu Hua
Executive Director and Chairman
12 June 2024

*This announcement has been prepared by the Company and its contents have been reviewed by the Company's Sponsor, Evolve Capital Advisory Private Limited (the "**Sponsor**") for compliance with relevant rules of the Singapore Exchange Securities Trading Limited ("**SGX-ST**").*

This announcement has not been examined or approved by the SGX-ST, and the SGX-ST assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement.

The details of the contact person for the Sponsor are: -

*Name: Mr. Jerry Chua (Registered Professional, Evolve Capital Advisory Private Limited) and Mr. Tan Jun Yong (Registered Professional, Evolve Capital Advisory Private Limited)
Address :138 Robinson Road, Oxley Tower, #13-02, Singapore 068906
Tel : (65) 6241 6626*